TEMPERATURE, MPa Temperature (C) Fl ex ur al S tr en gt h (M Pa ) Fl ex ur al M od ul us (G Pa ) 20 25 30 35 40 Glass/Epoxy High Temp Glass/Vinyl ester 1409040-10-60 0 300 600 900 1200 1500 Glass/Epoxy High Temp Epoxy/Glass Glass/Vinyl Ester 1901409040-10-60 200 400 600 800 1000 1200 14801280108088068048028080 FLEXURAL MODULUS VS. TEMPERATURE, GPa Temperature (C) 20 25 30 35 40 Glass/Epoxy High Temp Glass/Vinyl ester 1409040-10-60 0 300 600 900 1200 1500 Glass/Epoxy High Temp Epoxy/Glass Glass/Vinyl Ester 1901409040-10-60 200 400 600 800 1000 1200 14801280108088068048028080 FLEXURAL FATIGUE STRENGTH, MPa Cycles to Failure (in thousands) Fl ex ur al F at iq ue S tr en gt h (M Pa ) INSTALLATION INSTRUCTIONS Proper installation of composite springs from Avient is essential to achieve optimal performance and maximum service life.

Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 24 Capex / Revenue 2021E (%) AVIENT IS ASSET LIGHT Avient Specialty Formulators Other Chemical/Specialty Companies 2 3 2 2 3 3 3 4 3 3 4 4 4 5 5 5 5 7 7 8 23 A vi en t A vi en t (E xc l. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 84% Median: 77% HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $510M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of March 12, 2021 85 89 86 86 82 80 76 89 85 83 82 81 78 77 77 76 75 73 70 69 49 19 A vi en t K W R P P G R P M A V Y F U L G C P F M C IF F H X L U N V R E C L A S H B N R F O E E M N C E G R A H U N K R A S C L A L B Source: Peer data per Bloomberg market data as of March 12, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation implies an EBITDA multiple that is below specialty formulator peers and some of our more highly valued chemical peers. With the Clariant Masterbatch acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 26 Avient reflects 2021 estimated EBITDA of $510M OUR VALUATION VERSUS PEERS Avient Specialty Formulators Other Chemical/Specialty Companies 11.3 18.6 14.3 13.6 13.3 12.2 10.7 28.8 26.3 23.3 14.6 12.4 11.7 11.6 11.2 11.0 10.6 10.3 9.6 9.1 8.5 7.2 A vi en t K W R A V Y R P M P P G G C P F U L H X L A L B E C L IF F F M C A S H F O E B N R C E G R A E M N S C L U N V R K R A H U N Median: 11.2xMedian: 13.5x SUMMARY: WHY INVEST IN AVIENT?

Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 18 Capex / Revenue 2021E (%) AVIENT IS ASSET LIGHT Avient Specialty Formulators Other Chemical/Specialty Companies 2 3 2 2 2 3 3 4 3 3 3 4 4 5 5 5 6 7 7 8 24 A vi en t A vi en t (E xc l. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 84% Median: 77% HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $560M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of April 27, 2021 87 89 87 86 82 81 76 88 87 84 82 81 78 77 77 77 76 73 70 69 50 19 A vi en t K W R P P G R P M A V Y F U L G C P F M C IF F H X L U N V R E C L A S H C E B N R F O E E M N G R A H U N K R A S C L A L B Source: Peer data per Bloomberg market data as of April 27, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation with updated guidance implies an EBITDA multiple that is below specialty formulator peers and the majority of our chemical peers. With the Clariant Masterbatch acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 20 Avient reflects 2021 estimated EBITDA of $560M OUR VALUATION VERSUS PEERS Avient Specialty Formulators Other Chemical/Specialty Companies 10.2 17.7 16.0 14.9 14.6 11.6 11.1 26.7 24.0 22.8 14.3 12.7 11.5 11.2 11.1 11.0 10.3 10.1 9.5 9.4 8.3 7.0 A vi en t K W R A V Y R P M P P G G C P F U L A L B H X L E C L IF F F M C B N R A S H G R A F O E S C L E M N U N V R C E K R A H U N Median: 11.1xMedian: 14.8x SUMMARY: WHY INVEST IN AVIENT?

Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 17 Median: 3% Median: 5% Capex / Revenue 2021E (%) Source: Capital IQ market data as of August 24, 2020 AVIENT IS ASSET LIGHT Avient Specialty Formulators Other Chemical/Specialty Companies 83 86 85 84 80 56 89 83 82 82 78 76 76 75 71 70 68 63 61 58 14 A vi en t K W R R P M P P G F U L G C P F M C IF F U N V R B N R H X L E C L E M N F O E A S H C E G R A K R A H U N S C L A L B Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Source: Capital IQ market data as of August 24, 2020 Median: 84% Median: 75% HIGH FREE CASH FLOW CONVERSION 3.1x 2.6x 0.5x 1.9x 2.8x 3.1x 4.5x -0.1x 1.8x 1.9x 2.2x 2.3x 2.4x 2.9x 3.0x 3.0x 3.2x 3.4x 3.4x 3.8x 3.9x 4.8x A vi en t ( 20 P F ) A vi en t ( 21 E ) G C P P P G R P M K W R F U L S C L B N R H U N E C L C E F M C A S H H X L E M N G R A A L B IF F U N V R K R A F O E Net Debt / 2021E EBITDA (1) We typically operate at 2.5–3.0x net debt to EBITDA. Leverage is calculated as Total Debt – Cash / EBITDA 2. 2020 Pro forma for the acquisition of the Clariant Masterbatch business Source: Capital IQ market data as of August 24, 2020 Median: 2.8x Median: 3.0x (2 ) Avient Specialty Formulators Other Chemical/Specialty Companies THE CURRENT AVIENT VALUATION DISCONNECT 20 Our transformation and business model are still being understood, and as a result, we are currently trading at a discount to peer companies Our financial metrics are consistent with specialty formulator peers, yet our EBITDA multiple is at a 6.1x discount to peer companies Ongoing synergy capture is another value creation lever that is unique to Avient This creates a compelling investment opportunity 8.0 16.3 14.8 14.1 13.1 10.4 21.5 14.9 14.8 13.1 12.5 11.1 10.9 10.1 9.8 9.7 8.7 8.5 8.3 8.2 6.0 A vi en t K W R R P M G C P P P G F U L E C L IF F A L B H X L F M C F O E A S H C E S C L B N R H U N G R A E M N U N V R K R A Total Enterprise Value (1) / 2021E EBITDA (2) Our current valuation implies an EBITDA multiple that is significantly below specialty formulator peers and our historic valuations, when the company had considerable exposure to more cyclical and challenging end markets.

OUR VALUATION VERSUS PEERS Avient Specialty Formulators Other Chemical/Specialty Companies 5.4 8.5 10.1 10.0 15.7 15.0 14.2 12.7 10.2 25.0 19.7 17.7 13.2 12.3 10.0 9.9 8.9 8.5 8.3 6.6 A vi en t (2 01 1) A vi en t (2 01 6) A vi en t (2 02 1) A vi en t (T o da y) R P M K W R P P G A V Y F U L A L B E C L H X L A S H F M C B N R E M N U N V R C E S C L H U N Historic Multiple SUMMARY: WHY INVEST IN AVIENT?

Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 22 Capex / Revenue 2021E (%) AVIENT IS ASSET LIGHT Avient Specialty Formulators Other Chemical/Specialty Companies 2 3 2 2 2 3 3 6 2 3 4 4 5 5 5 6 6 6 7 9 25 A vi en t A vi en t (E xc l. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 83% Median: 76% HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $510M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of February 5, 2021 85 87 86 86 81 81 59 92 88 81 79 79 79 76 76 75 73 67 67 64 60 7 A vi en t P P G K W R R P M F U L A V Y G C P IF F F M C U N V R H X L E M N B N R E C L C E A S H F O E G R A H U N K R A S C L A L B Source: Peer data per Bloomberg market data as of February 5, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation implies an EBITDA multiple that is significantly below specialty formulator peers and our historic valuations, when the company had considerable exposure to more cyclical and challenging end markets. With the Clariant Masterbatch acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 24 Avient reflects 2021 estimated EBITDA of $510M OUR VALUATION VERSUS PEERS Avient Specialty Formulators Other Chemical/Specialty Companies 9.5 21.1 13.2 13.2 12.0 12.0 9.7 25.2 23.1 14.7 13.5 12.9 11.0 11.0 11.0 10.2 9.6 9.3 9.3 9.1 8.6 8.3 A vi en t K W R A V Y R P M G C P P P G F U L A L B E C L H X L IF F F M C G R A B N R F O E A S H C E S C L U N V R E M N H U N K R A Median: 11.0xMedian: 12.6x SUMMARY: WHY INVEST IN AVIENT?

https://www.grandviewresearch.com/industry-analysis/recycled-polyethylene-terephthalate-pet-market https://www.spglobal.com/platts/en/market-insights/blogs/petrochemicals/022621-us-plastic-recycling-pet-bottles-packaging-waste-investment https://ec.europa.eu/environment/topics/plastics/single-use-plastics_en Supply & Demand Currently, demand for rPET is outpacing the supply. https://www.spglobal.com/platts/en/market-insights/blogs/petrochemicals/022621-us-plastic-recycling-pet-bottles-packaging-waste-investment What’s Up Next for rPET?

KEY BENEFITS • EPBP bottle-to-bottle recyclability accredited • Non-nylon based product • Compatible with rPET (recommended for >up to 100% rPET content) • No scavenging delay or deactivation • Excellent bottle clarity • Fit to use in monolayer as well as multi-layer bottle structures * European Platform for Bottle Packaging 1 https://eur-lex.europa.eu/legal-content/EN/ LSU/?

This literature shall NOT operate as permission, recommendation, or inducement to practice any patented invention without permission of the patent owner. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 0 100 200 300 400 500 600 700 800 900 1000 Te ns ile S tr en gt h Re te nt io n Hours Submerged Tensile Strength Retention Standard Nylon 6/6, 50% Long Glass Fiber Moisture Resistant Nylon 6/6, 50% Long Glass Fiber Specialty Nylon 6/12, 50% Long Glass Fiber

Lo ss ta ng en t NEW TECHNOLOGIES REQUIRE NEW MATERIALS The rapid technology development requires new frequency ranges and bandwidths.